Research output per year
Research output per year
- 20 results
Search results
-
2024
Artificial Intelligence Technologies for Assessing Skin Lesions for Referral on the Urgent Suspected Cancer Pathway to Detect Benign Lesions and Reduce Secondary Care Specialist Appointments: Early Value Assessment
Walton, M. J., Llewellyn, A., Uphoff, N., Lord, J., Harden, M., Hodgson, R. & Simmonds, M. C., 28 Aug 2024, National Institute for Health and Care Excellence.Research output: Book/Report › Commissioned report
-
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer
Corbett, M. S., Deng, J., Uphoff, N., Walton, M. J., Lord, J., Fulbright, H. A., Dwan, K. & Hodgson, R., 7 Feb 2024, National Institute for Health and Care Excellence.Research output: Book/Report › Commissioned report
-
Selective internal radiation therapy with QuiremSpheres for treating unresectable advanced hepatocellular carcinoma (Partial review of TA688)
Uphoff, N., Lord, J., Anwer, S., Harden, M., Baker, M., Walton, M. J. & Nevitt, S. J., 3 Jul 2024, National Institute for Health and Care Excellence.Research output: Book/Report › Commissioned report
-
2023
Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma
Llewellyn, A., Murphy, P. J., Beresford, L., Walton, M. J., Fulbright, H. A., Harden, M., Eastwood, A. J. & Hodgson, R., 17 May 2023, National Institute for Health and Care Excellence.Research output: Book/Report › Commissioned report
-
Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer
Walton, M. J., Corbett, M. S., Dwan, K., Njoroge, M. W., Fulbright, H. A., Uphoff, N., Hodgson, R. & Dias, S., 11 May 2023, National Institute for Health and Care Excellence.Research output: Book/Report › Commissioned report
-
Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer
Walton, M. J., Corbett, M. S., Njoroge, M. W., Beresford, L., Harden, M., Hodgson, R. & Dias, S., 9 Feb 2023Research output: Book/Report › Commissioned report
-
Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer (Rapid Review of TA885)
Walton, M. J., Rodgers, M., Fulbright, H. A., Eastwood, A. J. & Hodgson, R., 13 Dec 2023, National Institute for Health and Care Excellence.Research output: Book/Report › Commissioned report
-
Pembrolizumab with chemotherapy for treating recurrent, persistent or metastatic cervical cancer [ID3798]Pembrolizumab with chemotherapy for treating recurrent, persistent or metastatic cervical cancer
Rodgers, M., Walton, M. J., Anwer, S., Corbett, M. S., Njoroge, M. W., Fulbright, H. A., Naik, R., Powell, M., Eastwood, A. J. & Hodgson, R., 29 Mar 2023, National Institute for Health and Care Excellence.Research output: Book/Report › Commissioned report
-
Tofacitinib for treating active ankylosing spondylitis: A Fast Track Appraisal. Evidence Review Group Report for the National Institute for Health and Care Excellence
Corbett, M. S., Walker, R. A. E., Anwer, S., Shepherd, L., Walton, M. J., Fulbright, H. A., Phung, H., Soares, M. O., Rothery, C., Duarte, A. I. & Dias, S., 18 Oct 2023, National Institute for Health and Care Excellence.Research output: Book/Report › Commissioned report
-
2022
OTL-200 for treating metachromatic leukodystrophy
Walton, M. J., Corbett, M. S., Melton, H. A., Claxton, L., Harden, M., Hodgson, R. & Simmonds, M. C., 28 Mar 2022, National Institute for Health and Care Excellence.Research output: Book/Report › Commissioned report
-
Tofacitinib for treating juvenile idiopathic arthritis: A Fast Track Appraisal. Evidence Review Group Report for the National Institute for Health and Care Excellence
Rodgers, M., Sharif, S., Walton, M. J., Harden, M., Dias, S. & Claxton, L., 2022Research output: Book/Report › Commissioned report
-
Upadacitinib for treating active ankylosing spondylitis: A Fast Track Appraisal. Evidence Review Group Report for the National Institute for Health and Care Excellence
Walker, R. A. E., Corbett, M. S., Beresford, L., Anwer, S., Duarte, A. I., Fulbright, H. A., Phung, H., Soares, M. O., Rothery, C., Walton, M. J. & Dias, S., 2022, National Institute for Health and Care Excellence.Research output: Book/Report › Commissioned report
-
2021
Baricitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis
Hodgson, R., Sharif, S., Beresford, L., Anwer, S., Walton, M. J., Wittmann, M., Harden, M., Khouja, C. L. & Dias, S., 3 Mar 2021, National Institute for Health and Care Excellence.Research output: Book/Report › Commissioned report
-
Betibeglogene autotemcel for treating transfusion-dependent beta-thalassaemia: A Single Technology Appraisal
Claxton, L., Corbett, M. S., Walton, M. J., Murphy, P. J., Anwer, S., Harden, M. & Dias, S., 11 Feb 2021, National Institute for Health and Care Excellence.Research output: Book/Report › Commissioned report
-
2020
Entrectinib for treating NTRK fusion-positive solid tumours
Hodgson, R., Llewellyn, A., Murphy, P. J., Claxton, L., Beresford, L., Walton, M. J., Glynn, D., Wright, K. & Dias, S., 12 Aug 2020, National Institute for Health and Care Excellence.Research output: Book/Report › Commissioned report
-
2019
Cerliponase alfa for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2)
Walton, M. J., O'Connor, J., Meader, N., Claxton, L., Harden, M., Woolacott, N. F. & Hodgson, R., 27 Nov 2019, National Institute for Health and Care Excellence.Research output: Book/Report › Commissioned report
-
Certolizumab pegol for treating moderate to severe plaque psoriasis
Walton, M. J., Sharif, S., Claxton, L., Wade, R., Hodgson, R., Harden, M. & Eastwood, A. J., 17 Apr 2019, National Institute for Health and Care Excellence.Research output: Book/Report › Commissioned report
-
Letermovir for the prophylaxis of cytomegalovirus reactivation or disease in people with seropositive-cytomegalovirus who have had an allogeneic haematopoietic stem cell transplant
Hodgson, R., O'Connor, J., Walton, M. J., Biswas, M. & Woolacott, N. F., 31 Jul 2019, National Institute for Health and Care Excellence.Research output: Book/Report › Commissioned report
-
2018
Tisagenlecleucel-T for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years
Walton, M. J., Sharif, S., Claxton, L., Wright, K., Hodgson, R. & Simmonds, M. C., 21 Dec 2018, National Institute for Health and Care Excellence.Research output: Book/Report › Commissioned report
-
2017
Ustekinumab for treating moderately to severely active CD after prior therapy
Hodgson, R., Biswas, M., Mebrahtu, T., Walton, M. J., Harden, M. & Woolacott, N. F., 12 Jul 2017, National Institute for Health and Care Excellence.Research output: Book/Report › Commissioned report